Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06631092 2026-05-26

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Phase 1/2 Recruiting

28 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05768139 2026-05-22

PIKALO-1

Phase 1/2 Recruiting

880 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Phase 1/2 Recruiting

81 enrolled

Breast

Breast Neoplasms

NCT06963905 2026-05-22

SIMONE

Phase 1/2 Recruiting

60 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1/2 Recruiting

205 enrolled

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07235176 2026-05-22

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Phase 1/2 Recruiting

300 enrolled

Breast

Advanced ER+/HER2- Breast Cancer

NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

22 enrolled

Breast

Breast Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Phase 1/2 Recruiting

460 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07100106 2026-05-18

MoonROSE

Phase 1/2 Recruiting

285 enrolled

Breast

Breast Neoplasms

NCT06827236 2026-05-15

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Phase 1/2 Recruiting

380 enrolled

Breast

Breast Neoplasms

NCT07339176 2026-05-14

OP-NEU-101

Phase 1/2 Recruiting

275 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT06110793 2026-05-13

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

54 enrolled

Breast

Breast Neoplasms

NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT06188520 2026-05-11

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06380816 2026-05-08

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Phase 1/2 Recruiting

167 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Recruiting

34 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06239194 2026-05-06

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

285 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

233 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05417594 2026-05-05

CERTIS1

Phase 1/2 Recruiting

695 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06998407 2026-05-04

AVZO-023-1001

Phase 1/2 Recruiting

380 enrolled

Breast

HR+/HER2- Breast Cancer

NCT05608252 2026-04-30

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms

NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Phase 1/2 Recruiting

32 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06726148 2026-04-27

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

280 enrolled

Breast

Breast Neoplasms

NCT05985655 2026-04-23

ELUCIDATE

Phase 1/2 Recruiting

230 enrolled

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT07115043 2026-04-23

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

60 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT05130801 2026-04-22

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Phase 1/2 Recruiting

55 enrolled

Breast

Breast Neoplasms

NCT05455619 2026-04-22

Amelia-1

Phase 1/2 Recruiting

52 enrolled

Breast

Breast Neoplasms, Hyperglycemia, Hyperinsulinism, Insulin Resistance

NCT06966453 2026-04-21

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1/2 Recruiting

100 enrolled

Breast

Breast Neoplasms

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06374459 2026-04-20

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1/2 Recruiting

152 enrolled

Breast

Breast Neoplasms

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

949 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

42 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

86 enrolled

Breast

Breast Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07198724 2026-04-09

ERADICATE

Phase 1/2 Recruiting

65 enrolled

Breast

Breast Neoplasms

NCT02830724 2026-04-06

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase 1/2 Recruiting

124 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05386108 2026-04-06

ELECTRA

Phase 1/2 Recruiting

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07510802 2026-04-06

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Phase 1/2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07389733 2026-04-03

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Recruiting

180 enrolled

Breast

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT05735080 2026-04-01

INX-315-01

Phase 1/2 Recruiting

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06732336 2026-03-31

HER2-PET Imaging in HER2-low Breast Cancers

Phase 1/2 Recruiting

40 enrolled

Breast

Breast Neoplasms

Clinical Trials

NeoB-Cap1

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

RAINFOL-01

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

PIKALO-1

MK-1022-009

SIMONE

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

MoonROSE

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

OP-NEU-101

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

CYCAD-1

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

CERTIS1

AVZO-023-1001

VS-6766+Abema+Fulv in Met HR+/HER- BC

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

ELUCIDATE

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Amelia-1

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

SELECT-2CAR

ERADICATE

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

ELECTRA

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

INX-315-01

HER2-PET Imaging in HER2-low Breast Cancers